Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer

Free Subscription 05.01.2026 1 Abdom Radiol (NY) 1 Adv Anat Pathol 1 Afr J Reprod Health 1 Am J Mens Health 1 Ann Oncol 1 Arch Environ Occup Health 1 ArXiv 3 Asian J Urol 1 Bioengineering (Basel) 2 BJU Int 2 BJUI Compass 1 Bladder Cancer 1 BMC Cancer 1 BMC Med Imaging 1 BMC Microbiol 1 BMC Urol 1 BMJ Support Palliat Care 1 Br J Radiol 1 Cancer Control 2 Cancer Sci 3 Cancers (Basel) 3 Cell Death Dis 2 Clin Epigenetics 1 Clin Genitourin Cancer 1 Cureus 1 Curr Oncol 1 Curr Urol Rep 3 Discov Oncol 1 Dose Response 1 ESMO Open 3 Eur Urol 1 Eur Urol Focus 2 Eur Urol Oncol 3 Eur Urol Open Sci 1 Food Sci Nutr 1 Front Cell Dev Biol 1 Front Genet 2 Front Immunol 2 Front Oncol 1 Future Oncol 2 Hum Mutat 1 IJU Case Rep 1 Int Immunopharmacol 1 Int J Nanomedicine 1 Int J Oncol 3 Int J Urol 1 Investig Clin Urol 1 iScience 1 J Cardiovasc Surg (Torino) 2 J Exp Clin Cancer Res 1 J Hematol Oncol 1 J Immunother 1 J Nanobiotechnology 1 J Toxicol Environ Health A 1 J Transl Med 1 Mamm Genome 1 Medicina (Kaunas) 1 Mol Biol Rep 1 Mol Cancer 1 Mol Cancer Res 1 Mol Oncol 1 Mol Pharmacol 1 Molecules 1 Proteomes 1 Sci Adv 1 South Asian J Cancer 1 Urol Oncol 2 Urol Pract 1 Vet Sci 3 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. ZHANG M, Chen C, Zeng X, Zhao Q, et al
   Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer.
   Abdom Radiol (NY). 2025 Dec 27. doi: 10.1007/s00261-025-05358.
   PubMed         Abstract available
   
   

   
   Adv Anat Pathol

2. PANER GP, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
   The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.
   Adv Anat Pathol. 2026;33:1-16.
   PubMed         Abstract available
   
   

   
   Afr J Reprod Health

3. WANG Y, Xue H, Xu S, Qin Y, et al
   Network toxicology analysis of hair dye components and their association with breast and bladder cancers.
   Afr J Reprod Health. 2025;29:204-216.
   PubMed         Abstract available
   
   

   
   Am J Mens Health

4. TAN J, Wang Y, Huang J, Dong B, et al
   Exploration of the Prognostic Value of PANoptosis-Related Genes in Bladder Cancer.
   Am J Mens Health. 2025;19:15579883251404985.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. GALSKY MD, Gschwend JE, Milowsky MI, Schenker M, et al
   Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
   Ann Oncol. 2026;37:69-78.
   PubMed         Abstract available
   
   

   
   Arch Environ Occup Health

6. CAINI S, Cosma C, Aprea MC, Saieva C, et al
   Heavy metals levels in pre-diagnostic serum of nonsmokers with cancer of the lung, bladder and prostate, and paired individuals.
   Arch Environ Occup Health. 2025;80:303-307.
   PubMed         Abstract available
   
   

   
   ArXiv

7. OLUMOYIN K, El Naqa L, Rejniak K
   Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data.
   ArXiv [Preprint]. 2025 Dec 17:arXiv:2512.15706.
   PubMed         Abstract available
   
   

   
   Asian J Urol

8. CERRATO C, Pandolfo SD, Kraft P, Ko DSC, et al
   Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature.
   Asian J Urol. 2025;12:471-477.
   PubMed         Abstract available
   
   
9. ANIS O, Bar V, Zundelevich A, Anil SM, et al
   Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich Cannabis sativa strains.
   Asian J Urol. 2025;12:534-543.
   PubMed         Abstract available
   
   
10. LAYMON M, Elsawy AA, Elsorougy A, Hashem A, et al
    Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.
    Asian J Urol. 2025;12:520-528.
    PubMed         Abstract available
    
    

    
    Bioengineering (Basel)

11. SONG M, Ren H, Wang L, Zhou Y, et al
    Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion.
    Bioengineering (Basel). 2025;12:1338.
    PubMed         Abstract available
    
    

    
    BJU Int

12. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
    Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
    PubMed         Abstract available
    
    
13. MENNES J, Akand M, Benijts R, Baekelandt L, et al
    Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
    BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
    PubMed         Abstract available
    
    

    
    BJUI Compass

14. MARTEL A, Raue L, Avogbe PH, Raisch J, et al
    Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.
    BJUI Compass. 2025;6:e70124.
    PubMed         Abstract available
    
    
15. WENG R, Phung TAT, Bell R, Dyrskjot L, et al
    Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
    BJUI Compass. 2025;6:e70131.
    PubMed         Abstract available
    
    

    
    Bladder Cancer

16. HANLON T, D'Andrea VD, Stelter I, Bekele R, et al
    Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.
    Bladder Cancer. 2025;11:23523735251409720.
    PubMed         Abstract available
    
    

    
    BMC Cancer

17. YANG IN, Liang CA, Wu CC, Xu QS, et al
    Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
    BMC Cancer. 2025;25:1900.
    PubMed         Abstract available
    
    

    
    BMC Med Imaging

18. XIAO B, Zeng Q, Peng X, He Q, et al
    An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.
    BMC Med Imaging. 2025;25:513.
    PubMed         Abstract available
    
    

    
    BMC Microbiol

19. MOUSA MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, et al
    Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.
    BMC Microbiol. 2025 Dec 27. doi: 10.1186/s12866-025-04572.
    PubMed        
    
    

    
    BMC Urol

20. AHMADI SP, Sadabadi F, Khoshbin B, Sheikhi Z, et al
    Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
    BMC Urol. 2025 Dec 28. doi: 10.1186/s12894-025-02006.
    PubMed        
    
    

    
    BMJ Support Palliat Care

21. WAI R, Sheahen B, Thomas B
    Severe itch from miliaria managed with propantheline: a case report.
    BMJ Support Palliat Care. 2025;16:85-87.
    PubMed         Abstract available
    
    

    
    Br J Radiol

22. LIU H, Jiang X, Wang T, Zhang G, et al
    Low-dose corticomedullary phase CT urography with artificial intelligence iterative reconstruction for bladder cancer evaluation.
    Br J Radiol. 2025 Dec 24:tqaf315. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Cancer Control

23. HU Z, Zeng D, Zhao X, Luo Y, et al
    Global Disparities and Temporal Trends in Prostate, Bladder, and Kidney Cancer Burden Among Men: A Systematic Analysis of 204 Countries (1990-2021).
    Cancer Control. 2025;32:10732748251411011.
    PubMed         Abstract available
    
    

    
    Cancer Sci

24. XUE Z, Qie Y, Shen C, Wu Z, et al
    Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 24. doi: 10.1111/cas.70311.
    PubMed         Abstract available
    
    
25. LI Q, Chen QF, Liao NQ
    Graph Neural Network-Based Multi-Scale Whole Slide Image Fusion for pT Staging of Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70292.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

26. CIGLIOLA A, Maiorano BA, Dengur D, Tateo V, et al
    The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2025;17:4017.
    PubMed         Abstract available
    
    
27. PLAGE H, Biernath N, Furlano K, Weinberger S, et al
    Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes.
    Cancers (Basel). 2025;17:3990.
    PubMed         Abstract available
    
    
28. HOSHI S, Meguro S, Makabe S, Onagi A, et al
    Immunosuppressive Role of Integrin beta8 in Recurrence After Bacillus Calmette-Guerin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2025;17:3964.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

29. LIU S, Liu T, Yang C, Mou Z, et al
    Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.
    Cell Death Dis. 2025 Dec 24. doi: 10.1038/s41419-025-08369.
    PubMed         Abstract available
    
    
30. WANG C, Li K, Wan S, Chen S, et al
    TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.
    Cell Death Dis. 2025;16:923.
    PubMed         Abstract available
    
    
31. YANG H, Liu X, Nie J, Wu S, et al
    USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.
    Cell Death Dis. 2025 Dec 23. doi: 10.1038/s41419-025-08297.
    PubMed         Abstract available
    
    

    
    Clin Epigenetics

32. SHI C, Xu J, Chen Q, Gao X, et al
    Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.
    Clin Epigenetics. 2025;17:204.
    PubMed         Abstract available
    
    
33. XU C, Ying W, He Y, Wu Y, et al
    Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
    Clin Epigenetics. 2025;17:203.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

34. NAIR MS, Scarborough J, Reddy CA, Bommireddy AR, et al
    Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
    Clin Genitourin Cancer. 2025;24:102477.
    PubMed         Abstract available
    
    

    
    Cureus

35. YAMAMOTO H, Oura S
    Possible Differentiation Between Recurrent Lymph Nodes of Bladder Cancer and Malignant Lymphoma on Ultrasound: A Case Report.
    Cureus. 2025;17:e98260.
    PubMed         Abstract available
    
    

    
    Curr Oncol

36. OZGUN G, Alexander A, Arbour G, Kollmannsberger C, et al
    Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.
    Curr Oncol. 2025;32:699.
    PubMed         Abstract available
    
    

    
    Curr Urol Rep

37. PENUNURI A, Greenberg E, Phillips J, Katims AB, et al
    The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.
    Curr Urol Rep. 2025;27:3.
    PubMed         Abstract available
    
    

    
    Discov Oncol

38. ZHONG MY, Zou XC, Chen PH
    Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy.
    Discov Oncol. 2025 Dec 27. doi: 10.1007/s12672-025-04275.
    PubMed         Abstract available
    
    
39. JIANG L, Ge W, Feng R, Ji L, et al
    Innovative AI model for bladder cancer diagnosis.
    Discov Oncol. 2025 Dec 20. doi: 10.1007/s12672-025-04278.
    PubMed         Abstract available
    
    
40. XU M, Yue S, Chen Z, Li R, et al
    hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.
    Discov Oncol. 2025 Dec 28. doi: 10.1007/s12672-025-04355.
    PubMed        
    
    

    
    Dose Response

41. LI C, Lv G, Xiong Z, Wang Z, et al
    Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-kappaB-Mediated FANCL Transcription in Bladder Cancer.
    Dose Response. 2025;23:15593258251411761.
    PubMed         Abstract available
    
    

    
    ESMO Open

42. MAIORANO BA, Cigliola A, Tateo V, Mercinelli C, et al
    Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
    ESMO Open. 2025;10:105862.
    PubMed         Abstract available
    
    

    
    Eur Urol

43. FILHO AM, Briganti A, Jemal A, Bray F, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
44. GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
    RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
    Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
    PubMed         Abstract available
    
    
45. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
    Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
    Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

46. JAZAYERI SB, DiNatale RG, Guske C, Harrs C, et al
    Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design.
    Eur Urol Focus. 2025 Dec 19:S2405-4569(25)00367.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

47. JURCZOK N, Dernbach G, Ebner B, Plage H, et al
    Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer.
    Eur Urol Oncol. 2025 Dec 30:S2588-9311(25)00333.
    PubMed         Abstract available
    
    
48. SORIA F, Liedberg F, Stahl E, Dominguez-Escrig JL, et al
    Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival
    Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328.
    PubMed         Abstract available
    
    

    
    Eur Urol Open Sci

49. MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
    Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Open Sci. 2025;83:54-63.
    PubMed         Abstract available
    
    
50. JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
    Bladder Cancer Burden in the USA: Population Scenarios for 2040.
    Eur Urol Open Sci. 2025;83:99-108.
    PubMed         Abstract available
    
    
51. ZHUANG J, Yu H, Cao Q, Bai R, et al
    Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
    Eur Urol Open Sci. 2025;83:36-45.
    PubMed         Abstract available
    
    

    
    Food Sci Nutr

52. GONG J, Sun D, Zheng Y, Mao C, et al
    Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.
    Food Sci Nutr. 2025;13:e71341.
    PubMed         Abstract available
    
    

    
    Front Cell Dev Biol

53. DI SPIRITO A, Zuccolotto G, Tosi A, Balkhi S, et al
    Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.
    Front Cell Dev Biol. 2025;13:1719978.
    PubMed         Abstract available
    
    

    
    Front Genet

54. ZHAO X, Liu H, Wang C, Guo F, et al
    Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
    Front Genet. 2025;16:1615167.
    PubMed         Abstract available
    
    

    
    Front Immunol

55. ZHANG J, Wang Y, Yan Q, Wang H, et al
    SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
    Front Immunol. 2025;16:1708324.
    PubMed         Abstract available
    
    
56. LI L, Ren F, Liu Z, Tian X, et al
    Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.
    Front Immunol. 2025;16:1668356.
    PubMed         Abstract available
    
    

    
    Front Oncol

57. XIANG J, Luo Y, Zhang B, Ke K, et al
    Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.
    Front Oncol. 2025;15:1670574.
    PubMed         Abstract available
    
    
58. HO PARK J, Lee H, Lee S, Hong SK, et al
    Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients.
    Front Oncol. 2025;15:1680595.
    PubMed         Abstract available
    
    

    
    Future Oncol

59. SHAMSEDDINE A, Abbas N, Temraz S, Al Darazi M, et al
    Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
    Future Oncol. 2025;21:3873-3884.
    PubMed         Abstract available
    
    

    
    Hum Mutat

60. HAN Y, Peng J, Yan W, Wu Z, et al
    FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression.
    Hum Mutat. 2025;2025:5947612.
    PubMed         Abstract available
    
    
61. LING Z, He S, Li T, Zhang J, et al
    Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.
    Hum Mutat. 2025;2025:5569005.
    PubMed         Abstract available
    
    

    
    IJU Case Rep

62. KANEMOTO S, Yamamoto S, Hino K, Tsuboi K, et al
    Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
    IJU Case Rep. 2025;9:e70119.
    PubMed         Abstract available
    
    

    
    Int Immunopharmacol

63. JIANG Y, Xu C, He W, Zhang C, et al
    First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq.
    Int Immunopharmacol. 2026;169:116060.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

64. CHEN J, Fu Y, Zhang Z, Zhao J, et al
    Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.
    Int J Nanomedicine. 2025;20:15235-15275.
    PubMed         Abstract available
    
    

    
    Int J Oncol

65. DU J, Shen H, Zeng T, Liu W, et al
    Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review).
    Int J Oncol. 2026;68:28.
    PubMed         Abstract available
    
    

    
    Int J Urol

66. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
    Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
    PubMed         Abstract available
    
    
67. FIORENTINO V
    Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
    PubMed        
    
    
68. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    PubMed         Abstract available
    
    

    
    Investig Clin Urol

69. SONG B, Lee H, Lee S, Hong SK, et al
    Preoperative serum albumin level is associated with postoperative short- and long-term renal function deterioration in patients who underwent radical cystectomy for bladder cancer.
    Investig Clin Urol. 2026;67:24-31.
    PubMed         Abstract available
    
    

    
    iScience

70. CHEN D, Li Z, Sui Y, Zeng Y, et al
    The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.
    iScience. 2025;28:114152.
    PubMed         Abstract available
    
    

    
    J Cardiovasc Surg (Torino)

71. D'ALESSIO I, Siloche D, Civilini E, Bissacco D, et al
    Aortic complications after treatment with bacillus Calmette-Guerin: a tertiary hospital experience and an update of the literature.
    J Cardiovasc Surg (Torino). 2025;66:532-542.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

72. LV J, Li K, Zhou J, Yu R, et al
    Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.
    J Exp Clin Cancer Res. 2025;44:324.
    PubMed         Abstract available
    
    
73. LI M, Liu T, Shi J, Zhou F, et al
    USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.
    J Exp Clin Cancer Res. 2025 Dec 23. doi: 10.1186/s13046-025-03621.
    PubMed        
    
    

    
    J Hematol Oncol

74. WANG JM, Xie HY, Zhang FH, Shu X, et al
    Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.
    J Hematol Oncol. 2025;18:110.
    PubMed         Abstract available
    
    

    
    J Immunother

75. HU K, Ma X, Luo L, Li P, et al
    FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.
    J Immunother. 2025 Dec 26. doi: 10.1097/CJI.0000000000000595.
    PubMed         Abstract available
    
    

    
    J Nanobiotechnology

76. LI C, Meng F, Lu C, Li A, et al
    A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.
    J Nanobiotechnology. 2025 Dec 29. doi: 10.1186/s12951-025-03935.
    PubMed         Abstract available
    
    

    
    J Toxicol Environ Health A

77. YANG CY, Ho SC, Chiu YW, Weng YH, et al
    Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
    J Toxicol Environ Health A. 2026 Jan 2:1-10. doi: 10.1080/15287394.2025.2611423.
    PubMed         Abstract available
    
    

    
    J Transl Med

78. HUANG J, Chen D, Ji G, Ma J, et al
    ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
    J Transl Med. 2025;23:1427.
    PubMed         Abstract available
    
    

    
    Mamm Genome

79. ZHI L, Yuan L
    Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/beta-catenin axis.
    Mamm Genome. 2025;37:20.
    PubMed         Abstract available
    
    

    
    Medicina (Kaunas)

80. KAYER A, Ozen A, Dinleyici EC
    Urinary Microbiota Composition in Treatment-Naive Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.
    Medicina (Kaunas). 2025;61:2240.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

81. YANG CW, Yen CH, Chien TM, Yu SY, et al
    Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation.
    Mol Biol Rep. 2025;53:234.
    PubMed         Abstract available
    
    

    
    Mol Cancer

82. DONG W, Bi J, Liu H, Yan D, et al
    Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
    Mol Cancer. 2025;24:309.
    PubMed        
    
    

    
    Mol Cancer Res

83. SIKDER RK, Ellithi M, Uzzo RN, Weader DJ, et al
    Editor's Note: Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
    Mol Cancer Res. 2026;24:84.
    PubMed        
    
    

    
    Mol Oncol

84. LI G, Tatarano S, Yoshino H, Saito S, et al
    Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.
    Mol Oncol. 2025 Dec 21. doi: 10.1002/1878-0261.70187.
    PubMed         Abstract available
    
    

    
    Mol Pharmacol

85. JANENZ J, Leipe A, Urban N, Schaefer M, et al
    Activation of TRPV3 channels in bladder cancer cells stimulates ATP release.
    Mol Pharmacol. 2025;108:100096.
    PubMed         Abstract available
    
    

    
    Molecules

86. WOLF I, Giess N, Roider C, Schultze-Seemann S, et al
    Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.
    Molecules. 2025;30:4802.
    PubMed         Abstract available
    
    

    
    Proteomes

87. VANTAGGIATO L, Frisenda M, Shaba E, Splendore C, et al
    Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Stage-Specific Molecular Signatures and Prognostic Biomarkers.
    Proteomes. 2025;13:65.
    PubMed         Abstract available
    
    

    
    Sci Adv

88. LEE J, Jung H, Kim EG, Ahn J, et al
    Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer.
    Sci Adv. 2026;12:eady0041.
    PubMed         Abstract available
    
    

    
    South Asian J Cancer

89. BIDI S, Nerli RB, Rangrez S, Ghagane SC, et al
    Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls.
    South Asian J Cancer. 2025;14:810-814.
    PubMed         Abstract available
    
    

    
    Urol Oncol

90. ANWAR I, Pandith AA, Rasool SUA, Manzoor U, et al
    Promoter hypermethylation drives a paradoxical up regulation of hTERT with prognostic implications in bladder cancer.
    Urol Oncol. 2025 Dec 31:110963. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available
    
    

    
    Urol Pract

91. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Incarcerated Patients Present with More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000961.
    PubMed         Abstract available
    
    
92. CARROLL TF, Bardot JP, David J, Zucker M, et al
    Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000962.
    PubMed         Abstract available
    
    

    
    Vet Sci

93. SPITZER A, Aupperle-Lellbach H, Spitzer M, Weidle S, et al
    DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.
    Vet Sci. 2025;12:1209.
    PubMed         Abstract available
    
    

    
    World J Urol

94. ROESSLER N, Miszczyk M, Gontero P, Miyajima K, et al
    Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.
    World J Urol. 2025;44:65.
    PubMed         Abstract available
    
    
95. PEKER P
    Correspondence regarding "Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German healt
    World J Urol. 2025;44:64.
    PubMed        
    
    
96. GOUHIZOUN O, Pattou M, Guena F, Khaddad A, et al
    Diagnostic accuracy of [18F]-FDG-PET/CT for lymph node staging in bladder cancer prior to radical cystectomy.
    World J Urol. 2025;44:59.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.